JP2012526844A - Ｍｃｉおよびアルツハイマー病の処置 - Google Patents

Ｍｃｉおよびアルツハイマー病の処置 Download PDF

Info

Publication number: JP2012526844A
Authority: JP; Japan
Prior art keywords: nifedipine; therapeutically effective; effective amount; nitrosonifedipine; pharmaceutical composition
Prior art date: 2009-05-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2012511013A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012526844A5 (es

Inventor

マークラベル，

バートリン，

Original Assignee

ザユニバーシティオブケンタッキーリサーチファウンデーション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-15

Filing date

2010-05-13

Publication date

2012-11-01

2010-05-13 Application filed by ザユニバーシティオブケンタッキーリサーチファウンデーション filed Critical ザユニバーシティオブケンタッキーリサーチファウンデーション

2012-11-01 Publication of JP2012526844A publication Critical patent/JP2012526844A/ja

2013-06-27 Publication of JP2012526844A5 publication Critical patent/JP2012526844A5/ja

Status Pending legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 93
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 216
229960001597 nifedipine Drugs 0.000 claims abstract description 201
239000003814 drug Substances 0.000 claims abstract description 134
239000000203 mixture Substances 0.000 claims abstract description 117
238000000034 method Methods 0.000 claims abstract description 113
208000010877 cognitive disease Diseases 0.000 claims abstract description 73
208000027061 mild cognitive impairment Diseases 0.000 claims abstract description 60
229940079593 drug Drugs 0.000 claims abstract description 49
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
-1 nitrosonifedipine Chemical compound 0.000 claims abstract description 27
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims abstract description 25
229940034208 thyroxine Drugs 0.000 claims abstract description 18
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims abstract description 18
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims abstract description 16
239000003937 drug carrier Substances 0.000 claims abstract description 8
102100033279 Prostaglandin-H2 D-isomerase Human genes 0.000 claims description 50
239000000090 biomarker Substances 0.000 claims description 45
108090000623 proteins and genes Proteins 0.000 claims description 39
230000000694 effects Effects 0.000 claims description 37
102000004169 proteins and genes Human genes 0.000 claims description 35
239000003795 chemical substances by application Substances 0.000 claims description 33
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 29
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 29
238000012360 testing method Methods 0.000 claims description 28
229940127291 Calcium channel antagonist Drugs 0.000 claims description 26
239000000480 calcium channel blocker Substances 0.000 claims description 26
230000002829 reductive effect Effects 0.000 claims description 26
102000013498 tau Proteins Human genes 0.000 claims description 24
108010026424 tau Proteins Proteins 0.000 claims description 24
108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims description 23
239000007787 solid Substances 0.000 claims description 21
238000004519 manufacturing process Methods 0.000 claims description 20
208000024891 symptom Diseases 0.000 claims description 20
239000006186 oral dosage form Substances 0.000 claims description 18
108010064397 amyloid beta-protein (1-40) Proteins 0.000 claims description 16
108010036933 Presenilin-1 Proteins 0.000 claims description 15
102000012412 Presenilin-1 Human genes 0.000 claims description 15
239000012530 fluid Substances 0.000 claims description 12
102000004127 Cytokines Human genes 0.000 claims description 11
108090000695 Cytokines Proteins 0.000 claims description 11
206010012289 Dementia Diseases 0.000 claims description 11
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 11
210000004556 brain Anatomy 0.000 claims description 10
101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 claims description 9
108030003866 Prostaglandin-D synthases Proteins 0.000 claims description 9
101150089041 aph-1 gene Proteins 0.000 claims description 9
230000002401 inhibitory effect Effects 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
108010071690 Prealbumin Proteins 0.000 claims description 8
102000009190 Transthyretin Human genes 0.000 claims description 8
238000013265 extended release Methods 0.000 claims description 8
238000007912 intraperitoneal administration Methods 0.000 claims description 8
238000007913 intrathecal administration Methods 0.000 claims description 8
238000001990 intravenous administration Methods 0.000 claims description 8
208000028698 Cognitive impairment Diseases 0.000 claims description 7
108090001005 Interleukin-6 Proteins 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 7
238000007918 intramuscular administration Methods 0.000 claims description 7
210000003169 central nervous system Anatomy 0.000 claims description 6
230000006999 cognitive decline Effects 0.000 claims description 6
238000007917 intracranial administration Methods 0.000 claims description 6
238000007914 intraventricular administration Methods 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
238000007920 subcutaneous administration Methods 0.000 claims description 6
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
102000046701 nicastrin Human genes 0.000 claims description 5
108700022821 nicastrin Proteins 0.000 claims description 5
210000002966 serum Anatomy 0.000 claims description 5
230000002159 abnormal effect Effects 0.000 claims description 4
239000000872 buffer Substances 0.000 claims description 4
230000003111 delayed effect Effects 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
230000004968 inflammatory condition Effects 0.000 claims description 4
239000000314 lubricant Substances 0.000 claims description 4
210000002381 plasma Anatomy 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
239000000375 suspending agent Substances 0.000 claims description 4
210000002700 urine Anatomy 0.000 claims description 4
108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
206010003445 Ascites Diseases 0.000 claims description 3
102100024633 Carbonic anhydrase 2 Human genes 0.000 claims description 3
101710167917 Carbonic anhydrase 2 Proteins 0.000 claims description 3
108010061642 Cystatin C Proteins 0.000 claims description 3
102000012192 Cystatin C Human genes 0.000 claims description 3
108010002352 Interleukin-1 Proteins 0.000 claims description 3
102000000589 Interleukin-1 Human genes 0.000 claims description 3
101710137011 Retinol-binding protein 4 Proteins 0.000 claims description 3
102100038246 Retinol-binding protein 4 Human genes 0.000 claims description 3
FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 claims description 3
239000002270 dispersing agent Substances 0.000 claims description 3
210000000416 exudates and transudate Anatomy 0.000 claims description 3
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
230000003340 mental effect Effects 0.000 claims description 3
102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims description 3
108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims description 3
210000003296 saliva Anatomy 0.000 claims description 3
108010081355 beta 2-Microglobulin Proteins 0.000 claims description 2
102000015736 beta 2-Microglobulin Human genes 0.000 claims description 2
239000011230 binding agent Substances 0.000 claims description 2
239000003974 emollient agent Substances 0.000 claims description 2
239000004094 surface-active agent Substances 0.000 claims description 2
229910017518 Cu Zn Inorganic materials 0.000 claims 1
229910017752 Cu-Zn Inorganic materials 0.000 claims 1
229910017943 Cu—Zn Inorganic materials 0.000 claims 1
102000019197 Superoxide Dismutase Human genes 0.000 claims 1
108010012715 Superoxide dismutase Proteins 0.000 claims 1
TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 claims 1
239000010408 film Substances 0.000 claims 1
239000007951 isotonicity adjuster Substances 0.000 claims 1
230000000087 stabilizing effect Effects 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 9
229940124597 therapeutic agent Drugs 0.000 description 82
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 62
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
210000004027 cell Anatomy 0.000 description 39
150000001875 compounds Chemical class 0.000 description 33
235000018102 proteins Nutrition 0.000 description 33
210000002919 epithelial cell Anatomy 0.000 description 26
201000010099 disease Diseases 0.000 description 24
208000035475 disorder Diseases 0.000 description 17
239000002609 medium Substances 0.000 description 17
230000026731 phosphorylation Effects 0.000 description 17
238000006366 phosphorylation reaction Methods 0.000 description 17
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
125000001931 aliphatic group Chemical group 0.000 description 15
125000004432 carbon atom Chemical group C* 0.000 description 15
238000002474 experimental method Methods 0.000 description 15
239000000523 sample Substances 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
125000000217 alkyl group Chemical group 0.000 description 13
230000007423 decrease Effects 0.000 description 13
238000001262 western blot Methods 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
239000002552 dosage form Substances 0.000 description 11
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 10
102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 10
125000003342 alkenyl group Chemical group 0.000 description 10
238000013270 controlled release Methods 0.000 description 10
239000000126 substance Substances 0.000 description 10
238000002965 ELISA Methods 0.000 description 9
210000001175 cerebrospinal fluid Anatomy 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
150000002832 nitroso derivatives Chemical class 0.000 description 9
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 8
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 8
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 8
108091008611 Protein Kinase B Proteins 0.000 description 8
210000002987 choroid plexus Anatomy 0.000 description 8
230000001149 cognitive effect Effects 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
239000003826 tablet Substances 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
101001071234 Arabidopsis thaliana SEC12-like protein 1 Proteins 0.000 description 7
125000000304 alkynyl group Chemical group 0.000 description 7
229940024606 amino acid Drugs 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 6
108090000312 Calcium Channels Proteins 0.000 description 6
102000003922 Calcium Channels Human genes 0.000 description 6
102000004889 Interleukin-6 Human genes 0.000 description 6
102000048176 Prostaglandin-D synthases Human genes 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000003920 cognitive function Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
229960000715 nimodipine Drugs 0.000 description 6
230000037361 pathway Effects 0.000 description 6
238000013268 sustained release Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
238000000576 coating method Methods 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000010586 diagram Methods 0.000 description 5
229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 5
239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
239000008101 lactose Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
229960001783 nicardipine Drugs 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
239000000843 powder Substances 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
238000012545 processing Methods 0.000 description 5
239000007909 solid dosage form Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 4
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
206010003571 Astrocytoma Diseases 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
208000012902 Nervous system disease Diseases 0.000 description 4
206010029260 Neuroblastoma Diseases 0.000 description 4
208000025966 Neurological disease Diseases 0.000 description 4
FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 4
239000012124 Opti-MEM Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
125000002723 alicyclic group Chemical group 0.000 description 4
229960000528 amlodipine Drugs 0.000 description 4
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
238000011888 autopsy Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000006143 cell culture medium Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003636 conditioned culture medium Substances 0.000 description 4
238000004624 confocal microscopy Methods 0.000 description 4
210000003618 cortical neuron Anatomy 0.000 description 4
125000004093 cyano group Chemical group *C#N 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
229960003580 felodipine Drugs 0.000 description 4
210000001652 frontal lobe Anatomy 0.000 description 4
239000000499 gel Substances 0.000 description 4
208000005017 glioblastoma Diseases 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
238000012744 immunostaining Methods 0.000 description 4
229960004427 isradipine Drugs 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000463 material Substances 0.000 description 4
229960005366 nilvadipine Drugs 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000006187 pill Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
208000032612 Glial tumor Diseases 0.000 description 3
206010018338 Glioma Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
101710138657 Neurotoxin Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000004913 activation Effects 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
125000003282 alkyl amino group Chemical group 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
230000001934 delay Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
239000002581 neurotoxin Substances 0.000 description 3
231100000618 neurotoxin Toxicity 0.000 description 3
125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 3
125000000018 nitroso group Chemical group N(=O)* 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
210000000664 rectum Anatomy 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
230000007017 scission Effects 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
239000001993 wax Substances 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 2
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108050005377 Phosphatidylinositol kinases Proteins 0.000 description 2
102000017343 Phosphatidylinositol kinases Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 2
101710139715 Superoxide dismutase [Cu-Zn] Proteins 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000032683 aging Effects 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
229950004646 azelnidipine Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229960004916 benidipine Drugs 0.000 description 2
QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 2
230000008238 biochemical pathway Effects 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
125000004452 carbocyclyl group Chemical group 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000008859 change Effects 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
229960003597 clevidipine Drugs 0.000 description 2
KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
UMQHJQGNGLQJPF-UHFFFAOYSA-N dehydronifedipine Chemical compound COC(=O)C1=C(C)N=C(C)C(C(=O)OC)=C1C1=CC=CC=C1[N+]([O-])=O UMQHJQGNGLQJPF-UHFFFAOYSA-N 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
238000013399 early diagnosis Methods 0.000 description 2
229950003102 efonidipine Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 2
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
239000007897 gelcap Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
229960004294 lercanidipine Drugs 0.000 description 2
ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229960003963 manidipine Drugs 0.000 description 2
ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
230000003557 neuropsychological effect Effects 0.000 description 2
230000002887 neurotoxic effect Effects 0.000 description 2
229960005425 nitrendipine Drugs 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000013610 patient sample Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229940113125 polyethylene glycol 3000 Drugs 0.000 description 2
229950004891 pranidipine Drugs 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
108091008598 receptor tyrosine kinases Proteins 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
RMZQSAMHIQBMLW-UHFFFAOYSA-N 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC=C1[N+]([O-])=O RMZQSAMHIQBMLW-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000271566 Aves Species 0.000 description 1
230000007466 Aβ secretion Effects 0.000 description 1
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
108091006096 Gα12 Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001071233 Homo sapiens PHD finger protein 1 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
241000270322 Lepidosauria Species 0.000 description 1
238000003222 MTT reduction assay Methods 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
208000036110 Neuroinflammatory disease Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
102100036879 PHD finger protein 1 Human genes 0.000 description 1
102000038030 PI3Ks Human genes 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000009328 Perro Species 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
101150111584 RHOA gene Proteins 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
231100000569 acute exposure Toxicity 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
239000007894 caplet Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
229960003020 cilnidipine Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000019771 cognition Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
239000000104 diagnostic biomarker Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
MUZLTKGYFZENFW-UHFFFAOYSA-N dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)N=C(C)C(C(=O)OC)=C1C1=CC=CC=C1N=O MUZLTKGYFZENFW-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940120402 donepezil and memantine Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000005370 electroosmosis Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
230000004907 flux Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
229960003980 galantamine Drugs 0.000 description 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
108091006093 heterotrimeric G proteins Proteins 0.000 description 1
102000034345 heterotrimeric G proteins Human genes 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000006951 hyperphosphorylation Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003140 lateral ventricle Anatomy 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000006996 mental state Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000006082 mold release agent Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000013642 negative control Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002682 neurofibrillary tangle Anatomy 0.000 description 1
230000003959 neuroinflammation Effects 0.000 description 1
230000007512 neuronal protection Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000003605 opacifier Substances 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000005297 pyrex Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
102000000568 rho-Associated Kinases Human genes 0.000 description 1
108010041788 rho-Associated Kinases Proteins 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229960004136 rivastigmine Drugs 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000001338 self-assembly Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
125000005624 silicic acid group Chemical class 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
229940001482 sodium sulfite Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
238000013517 stratification Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001296 transplacental effect Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2012511013A 2009-05-15 2010-05-13 Ｍｃｉおよびアルツハイマー病の処置 Pending JP2012526844A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US21645209P	2009-05-15	2009-05-15
US61/216,452		2009-05-15
US23455109P	2009-08-17	2009-08-17
US61/234,551		2009-08-17
PCT/US2010/034721 WO2010132671A1 (en)	2009-05-15	2010-05-13	Treatment of mci and alzheimer's disease

Publications (2)

Publication Number	Publication Date
JP2012526844A true JP2012526844A (ja)	2012-11-01
JP2012526844A5 JP2012526844A5 (es)	2013-06-27

Family

ID=43069025

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2012511013A Pending JP2012526844A (ja)	2009-05-15	2010-05-13	Ｍｃｉおよびアルツハイマー病の処置

Country Status (7)

Country	Link
US (1)	US20100292281A1 (es)
EP (1)	EP2429992A4 (es)
JP (1)	JP2012526844A (es)
AU (1)	AU2010249015A1 (es)
CA (1)	CA2761298A1 (es)
MX (1)	MX2011012015A (es)
WO (1)	WO2010132671A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8067008B2 (en)	2004-08-23	2011-11-29	Yeda Research And Development Co.	Peptide inhibitors for mediating stress responses
ES2690304T3 (es)	2005-09-30	2018-11-20	Io Therapeutics, Llc	Tratamiento del cáncer con agonistas específicos de RXR
CA2836503C (en)	2011-05-23	2020-09-22	Yeda Research And Development Co. Ltd.	Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2013022953A2 (en) *	2011-08-08	2013-02-14	Eugenia Wang	Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
US10653650B2 (en)	2011-12-13	2020-05-19	Io Therapeutics, Inc.	Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN104114171A (zh)	2011-12-13	2014-10-22	Io治疗公司	使用rxr激动剂的自身免疫紊乱的治疗
MX2014015310A (es)	2012-06-15	2015-07-06	Found Biomedical Res & Innov	Agente profilactico y/o terapeutico para el deterioro cognoscitivo leve.
US8901305B2 (en) *	2012-07-31	2014-12-02	Bristol-Myers Squibb Company	Aryl lactam kinase inhibitors
US20150045353A1 (en) *	2013-08-09	2015-02-12	Neurogenetic Pharmaceuticals, Inc.	Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
HK1255075A1 (zh)	2015-10-31	2019-08-02	Io治疗公司	使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
JP7169647B2 (ja)	2016-03-10	2022-11-11	アイオーセラピューティクスインコーポレイテッド	Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの筋肉障害の治療
CN115227826A (zh)	2016-03-10	2022-10-25	Io治疗公司	Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
EP3684348A4 (en) *	2017-09-20	2021-08-18	IO Therapeutics, Inc.	TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
US10966950B2 (en)	2019-06-11	2021-04-06	Io Therapeutics, Inc.	Use of an RXR agonist in treating HER2+ cancers
MX2024006978A (es)	2021-12-07	2024-07-19	Io Therapeutics Inc	Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004110354A2 (en) *	2003-05-15	2004-12-23	Roskamp Research, Llc	Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
WO2006109164A2 (en) *	2005-04-15	2006-10-19	Research & Innovation Soc. Coop. A R.L.	A method for preventing, delaying or reverting abnormal amyloid deposition
JP2007091664A (ja) *	2005-09-29	2007-04-12	Univ Of Tokushima	細胞膜保護剤
JP2007512338A (ja) *	2003-11-21	2007-05-17	メモリー・ファーマシューティカルズ・コーポレイション	Ｌ型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
WO2007064010A1 (ja) *	2005-12-02	2007-06-07	Mochida Pharmaceutical Co., Ltd.	アルツハイマー型認知症予防・治療剤
WO2008051291A2 (en) *	2006-04-11	2008-05-02	Ordway Research Institute	Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) *	2007-09-20	2009-04-09	Univ Of Tokushima	Ｉｃａｍ−１発現抑制剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2126533A1 (de) *	1971-05-28	1972-12-14	Merck Patent Gmbh, 6100 Darmstadt	Verfahren zur Herstellung pharma zeutischer Zubereitungen
DE4342196A1 (de) *	1993-12-10	1995-06-14	Bayer Ag	Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5073543A (en) *	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) *	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) *	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en) *	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en) *	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1270594B (it) *	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6066642A (en) *	1996-01-29	2000-05-23	The United States Of America As Represented By The Department Of Health And Human Services	Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
AU2794199A (en) *	1998-02-26	1999-09-15	Robertas Bunevicius	Thyroid hormone replacement using sustained release triiodothyronine
CA2325353A1 (en) *	1998-04-08	1999-10-14	Oregon Health Sciences University	Enhancement of cellular gallium uptake
BRPI0518151A2 (pt) *	2004-10-13	2009-06-16	Ablynx Nv	polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
JP2008539255A (ja) *	2005-04-26	2008-11-13	マイクロビアインコーポレーテッド	高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
WO2007112288A2 (en) *	2006-03-23	2007-10-04	Mount Sinai School Of Medicine	Cardiovascular composition and use the same for the treatment of alzheimers disease

2010
- 2010-05-13 WO PCT/US2010/034721 patent/WO2010132671A1/en not_active Ceased
- 2010-05-13 CA CA2761298A patent/CA2761298A1/en not_active Abandoned
- 2010-05-13 EP EP10775535A patent/EP2429992A4/en not_active Withdrawn
- 2010-05-13 US US12/779,345 patent/US20100292281A1/en not_active Abandoned
- 2010-05-13 AU AU2010249015A patent/AU2010249015A1/en not_active Abandoned
- 2010-05-13 MX MX2011012015A patent/MX2011012015A/es not_active Application Discontinuation
- 2010-05-13 JP JP2012511013A patent/JP2012526844A/ja active Pending

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004110354A2 (en) *	2003-05-15	2004-12-23	Roskamp Research, Llc	Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
JP2007512338A (ja) *	2003-11-21	2007-05-17	メモリー・ファーマシューティカルズ・コーポレイション	Ｌ型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
WO2006109164A2 (en) *	2005-04-15	2006-10-19	Research & Innovation Soc. Coop. A R.L.	A method for preventing, delaying or reverting abnormal amyloid deposition
JP2007091664A (ja) *	2005-09-29	2007-04-12	Univ Of Tokushima	細胞膜保護剤
WO2007064010A1 (ja) *	2005-12-02	2007-06-07	Mochida Pharmaceutical Co., Ltd.	アルツハイマー型認知症予防・治療剤
WO2008051291A2 (en) *	2006-04-11	2008-05-02	Ordway Research Institute	Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) *	2007-09-20	2009-04-09	Univ Of Tokushima	Ｉｃａｍ−１発現抑制剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5012013695; ＪＡＶＩＤＮＩＡ: 'ＰＨＯＴＯＳＴＡＢＩＬＩＴＹ　ＤＥＴＥＲＭＩＮＡＴＩＯＮ　ＯＦ　ＣＯＭＭＥＲＣＩＡＬＬＹ　ＡＶＡＩＬＡＢＬＥ　ＮＩＦＥＤＩＰＩＮＥ　ＯＲＡＬ　ＤＯＳＡＧＥ　ＦＯＲＭＳ　ＩＮ　ＩＲＡＮ' ＩＲＡＮＩＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ　ＲＥＳＥＡＲＣＨＶ２　Ｎ２, 2003, Ｐ１１１-１１５ *
JPN6012058681; 堀ノ内裕也ら: 'Ｎｉｆｅｄｉｐｉｎｅ代謝物の細胞保護効果の検討' 日本循環薬理学会口演要旨集ｖｏｌ．１６, 2006, ｐ．６０ *
JPN6014021496; 小川聡ら、病院薬学、１９９０年、１６巻３号、１８９-１９７頁 *
JPN6014021497; Ｐ．Ｐｉｅｔｔａ，　ｅｔ　ａｌ．，　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｒｏｍａｔｏｇｒａｐｈｙ，　１９８１，　２１０（３），　ｐｐ５１６-２１ *

Also Published As

Publication number	Publication date
AU2010249015A1 (en)	2011-11-24
MX2011012015A (es)	2012-04-30
WO2010132671A1 (en)	2010-11-18
US20100292281A1 (en)	2010-11-18
EP2429992A4 (en)	2012-11-28
EP2429992A1 (en)	2012-03-21
CA2761298A1 (en)	2010-11-18

Publication	Publication Date	Title
JP2012526844A (ja)	2012-11-01	Ｍｃｉおよびアルツハイマー病の処置
JP2012526844A5 (es)	2013-06-27
JP2013526518A (ja)	2013-06-24	Ｍｃｉおよびアルツハイマー病の処置
Das et al.	2019	A close look at BACE1 inhibitors for Alzheimer’s disease treatment
US20200338040A1 (en)	2020-10-29	Methods for treating alzheimer's disease and related disorders
EP1383465B1 (en)	2011-08-10	Acute pharmacologic augmentation of psychotherapy with d-cycloserine
US9968574B2 (en)	2018-05-15	Treatment of MCI and Alzheimer's disease
US20220054454A1 (en)	2022-02-24	Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
JP2010531854A (ja)	2010-09-30	抗アミロイド剤としてのピレンゼピンおよびその誘導体
TW202425995A (zh)	2024-07-01	減少與神經退化疾病相關的神經退化的方法
CN101883564B (zh)	2013-10-16	使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
Lovell et al.	2010	Treatment of MCI and Alzheimer's Disease
Samentar et al.	2021	A novel hybrid protein promotes Aβ clearance and reduces inflammatory response through MerTK
KR20130030011A (ko)	2013-03-26	뇌손상에 의한 전두엽 기능장애 모델 동물 및 전두엽 기능장애의 개선용 조성물
Cavanagh	2016	The Role of Tumor Necrosis Factor-α in a Prodromal Mouse Model of Alzheimer's Disease
Ranade et al.	0	TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW
HK1212603A1 (zh)	2016-06-17	治疗阿尔茨海默病及相关疾病的组合疗法

Legal Events

Date	Code	Title	Description
2013-05-11	A524	Written submission of copy of amendment under article 19 pct	Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20130510
2013-05-11	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130510
2014-05-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140527
2014-11-21	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141120